ORBIMED ADVISORS LLC - 15 Aug 2023 Form 4 Insider Report for Galecto, Inc. (GLTO)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
17 Aug 2023, 16:40:30 UTC
Prior SEC filing
21 Sep 2023
Next SEC filing
31 Aug 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC

Key filing fact

ORBIMED ADVISORS LLC filed Form 4 for Galecto, Inc. (GLTO) on 17 Aug 2023.

Key facts

  • This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for Galecto, Inc. (GLTO).
  • 3 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 17 Aug 2023, 16:40.

Change

  • Previous filing in this sequence was filed on 21 Sep 2023.
  • Current net transaction value: -$617,010.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GLTO transaction

Common Stock

Sale

Transaction value
$28,745
Shares
-38,327
Change %
-28%
Price
$0.7500
Shares after
97,204
Date
15 Aug 2023
Ownership
See footnotes
Footnotes
F1, F4
GLTO transaction

Common Stock

Sale

Transaction value
$186,614
Shares
-248,819
Change %
-28%
Price
$0.7500
Shares after
631,048
Date
15 Aug 2023
Ownership
See footnotes
Footnotes
F2, F4
GLTO transaction

Common Stock

Sale

Transaction value
$401,650
Shares
-535,534
Change %
-26%
Price
$0.7500
Shares after
1,510,375
Date
15 Aug 2023
Ownership
See footnotes
Footnotes
F3, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

ORBIMED ADVISORS LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis.

Footnote F2

These securities are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OrbiMed Israel") is the general partner of OIP II and OrbiMed Advisors Israel II Limited ("OrbiMed Limited") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II.

Footnote F3

These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII.

Footnote F4

Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .